Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-627-6 | CAS number: 17270-01-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
28-day Oral (Gavage) Toxicity Study with ADK STAB FP-800 in rats according to OECD 407 of 1995:
- Doses / Study Design: 0 (vehicle control), 25, 150, 1000 mg/kg bw/day on 28 consecutive days.
- Study Design: 5 animals/sex/dose of all dose groups, sacrificed on Day 29,
+ 10 recovery animals (5M+5F) per control and high dose groups killed on Day 43 after 14 recovery days.
- NOAEL: 1000 mg/kg/day.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Well documented and reported study fully adequate for assessment. The study was conducted according to internationally accepted technical guidelines and in compliance with GLP in a recognized contract research organization.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- of 1995
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: References detailed in Robust study summary section "Any other information on materials and methods incl. tables"
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Sprague Dawley rats, strain: Crl:CD(SD)(SPF) with appropriate range of bodyweight at study start.
- Source: Charles River Japan Hino Breeding Center.
- Age at study initiation (treatment start): Ca. 5 weeks.
- Assignment to dose groups: By bodyweight stratified randomization prior to treatment start.
- Weight at study initiation (treatment start): Males: minimum 145 g, maximum 167 g,
Females: minimum 117 g, maximum 137 g.
- Housing: Inside a barriered rodent facility in hanging stainless steel cages with wire mesh floor:
for quarantine and acclimation: In groups of 3 or 5/cage by sex
after assignment to dose groups: At 1 animal/cage
During urine collection individual housing in metabolism cages (15-17 h, treatment day 28 & recovery day 14).
- Diet (ad libitum, except during urine collection): MF pelleted diet (Lot No. 0803, Oriental Yeast)
- Water (ad libitum, also during urine collection): Chlorinated water from Hita City supply.
- Acclimation period (including 6 days of quarantine): 9 days before treatment start.
Diet and housing materials were autoclaved at 121°C prior to use. Routine analysis of the batch of diet used and drinking water produced results within acceptable ranges.
ENVIRONMENTAL CONDITIONS
The animal room was maintained at (target ranges for temperature and relative humidity):
- Temperature (°C): 22 to 25°C
- Relative Humidity (%): 56 ± 8 %
- Photoperiod (artificial lighting): 12 hrs day / 12 hrs night
- Rate of air exchange: 10 to 15 changes/h - Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Details on oral exposure:
- - Concentration in vehicle: The concentration of the test material in vehicle varied between dose groups thus allowing constant dosage volume in terms of mL/kg bw/day.
- Amount (dose volume by gavage): 10 mL/kg bw/day.
- For concentrations of test material in vehicle at different dose levels, see Table 1 in "Any other information on materials and methods incl. tables"
- Dosing formulations were prepared fresh at about weekly intervals before (for analytical confirmation of concentration) and during the treatment period.
- Justification for choice of vehicle:
In a vehicle trial, the test material was not dissolved in purified water or olive oil, but was satisfactorily suspended in olive oil, when prepared at 10% w/v. Therefore, olive oil was chosen as a vehicle. In addition, in the present main study, satisfactory concentrations, homogeneity and stability of the test material in the chosen vehicle were confirmed. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- - Test material stability during the dosing period was confirmed by IR spectrophotometry.
- Chemical analysis of test material formulations by high performance liquid chromatography with UV-VIS detection (HPLC/UV-VIS).
- Chemical analysis confirmed that the prepared formulations were within 99.5 to 102% of the corresponding nominal concentration (conducted
prior to treatment start, at all dose levels) .
- Homogeneity of the test material formulations and their stability over 8 days were confirmed (by HPLC/UV-VIS) at the high and low dose levels. - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Once daily, 7 days/week on 28 consecutive days
- Remarks:
- Doses / Concentrations:
0 (vehicle control), 25, 150, 1000 mg/kg bw/day
Basis:
actual ingested - No. of animals per sex per dose:
- 5 (Main study animals; all dose groups)
5 (Recovery animals; only vehicle control and high dose group) - Control animals:
- yes, concurrent vehicle
- Details on study design:
- Dose selection rationale:
Dose selection in the present 28-day oral toxicity study was based on a 7-day repeated dose range-finding oral toxicity study with doses of 0 (vehicle control), 25, 250, 500 and 1000 mg/kg bw/day. In the 7-day study, adverse effects attributable to treatment with the test material were not evident. Salivation seen after administration was not considered to represent an adverse effect.
Study design of the present 28-day study:
5 m + 5 f / main study group: Vehicle control, low, mid and high dose groups, termination after 28 treatment days
5 m + 5 f / recovery group: Vehicle control and high dose groups, termination after 28 treatment days followed by 14 treatment-free recovery days - Positive control:
- Not applicable.
- Observations and examinations performed and frequency:
- The following observations and examinations were performed on all animals:
- Clinical signs and mortality
during treatment period: Four times a day (before, during and just after dosing during the morning, and in the afternoon)
during recovery period: Twice daily
- Detailed clinical observations
and arena observations: Before treatment start and once a week during the treatment and recovery periods **.
- Functional Observation Battery:* During treatment week 4 on all animals.
- Body weights: At dose group allocation (during acclimation) and twice a week during the treatment and recovery periods.
In addition, immediately prior to necropsy for determination of organ to bodyweight ratios.
- Food consumption: At dose group allocation, once or twice a week during the treatment period and twice a week during recovery.
* FOB including sensory reactivity tests (approach, contact/touch, tail pinching and auditory startle, pupillary & righting reflexes)**, grip strength**
and locomotor activity.
** "Blind" recording, i.e. the treatment or dose level were not disclosed during recording.
- Haematology/Clinical chemistry (after overnight fasting for 16 to 20 hours with water available ad libitum):
main study animals: At completion of the treatment period.
recovery animals: At completion of the treatment-free recovery period
- Urinalysis (urine accumulated for 15-17 hours).
main study animals: At the end of the treatment period
recovery animals: At the end of the recovery period
Animals were deprived of food but had access to water during urine collection in metabolism cages.
Hematology parameters examined:
Red blood cell count, white blood cell count, platelet count, reticulocyte count, hemoglobin concentration, hematocrit value, differential leukocyte counts,
protrombin time, activated partial thromboplastin time, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration.
Blood chemistry parameters examined:
Total protein, albumin, A/G ratio, blood urea nitrogen, creatinine, glucose, total cholesterol, total bilirubin, triglyceride, sodium, potassium,
chloride, calcium, inorganic phosphorus, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase,
cholinesterase.
Urinary parameters examined:
Volume, colour, turbidity, osmotic pressure, pH, protein, glucose, blood, sediment (red blood cells, white blood cells, epithelial cells, casts crystals). - Sacrifice and pathology:
- - Sacrifice and gross pathology (full macroscopic external and internal examination with tissue collection):
Main study animals: End of treatment period (Day 29)
Recovery animals: End of treatment free recovery period (Day 43)
- Organs Weights: The following organs of all main study and recovery animals were weighed at necropsy:
Brain, heart, liver, spleen, thymus, adrenals, kidneys, testes, epididymides, ovaries.
- Histopathology of main study animals for the vehicle control and 1000 mg/kg bw/day groups (organs microscopically examined):
Brain (cerebrum, cerebellum, pons), eye balls, pituitary gland, thyroid, parathyroids, heart, thymus, liver, spleen, adrenals, kidneys, testes,
epididymides, prostate, seminal vesicles, ovaries, uterus, vagina, lungs, trachea, forestomach, glandular stomach, duodenum, jejunum, ileum, caecum, colon, rectum, lymph node (axillary, mesenteric), urinary bladder, spinal cord, sciatic nerve, bone marrow (femur).
All dose groups: Gross lesions - Other examinations:
- No
- Statistics:
- Data regarding body weights (excluding those at the time of necropsy), food consumption, hematological examinations, blood chemical examinations, urine volume, urine osmotic pressure, organ weights and FOB metrical data (grip strength and locomotor activity counts) were analyzed by using the Bartlett's test for homogeneity of variance. If the variances were homogeneous at a significance level of 5%, one way analysis of variance was performed. If there was a significant difference in this analysis, the difference between the vehicle control group and each of the treatment group was analyzed by the Dunnett's test. If the variances were not homogeneous, the Kruskal-Wallis's test was used. If there was a significant difference in this analysis, the difference between the vehicle control group and each of the treatment group was analyzed by the nonparametric Dunnett's test.
FOB numerical data (defecation and urination) was analyzed by using the Kruskal-Wallis's test. If there was a significant difference in this analysis, the difference between the vehicle control group and each of the treatment group was analyzed by the nonparametric Dunnett's test. - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- but not adverse
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- but not adverse
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- statistically significant changes not considered to be toxicologically relevant
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- statistically significant changes not considered to be toxicologically relevant
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- statistically significant changes not considered to be toxicologically relevant
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- In view of a lack of dose relationship, a statistically significant reduction in forelimb grip strength in males at 150 mg/kg/day was not considered to be toxicologically relevant.
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- In view of a lack of dose relationship, a statistically significant reduction in epididymis weight in males at 150 mg/kg/day was not considered to be toxicologically relevant.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- incidental findings, toxicologically not relevant
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- incidental spontaneous background lesions. Toxicologically, these did not distinguish treated animals from concurrent controls.
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY
There were no deaths. Toxicologically relevant clinical signs or effects on sensory reactivity, grip strength or motor activity were not evident. Therefore, sensorimotor function was not tested on recovery animals. Salivation occurring just after administration in one female at 25 mg/kg/day and in both sexes at 150 and 1000 mg/kg/day increasing in number of affected animals with increasing dose was not considered to be an indication of neurotoxicity or to represent an adverse effect. The number of urinations in males of the 1000 mg/kg/day dose group statistically significantly higher than in concurrent controls was restricted to treatment week 4. In the absence of histopathological changes in urinary organs and of overt nervous effects in the present study, this statistically significant difference was not attributed to treatment with the test material. Statistically significantly lower forelimb grip strength in males at 150 mg/kg/day than in concurrent controls was not considered to be toxicologically relevant, because there were a lack of dose relationship in males and no confirmatory findings in females.
BODY WEIGHT AND FOOD CONSUMPTION
There were no adverse effects of treatment with the test material on bodyweight or food consumption.
HAEMATOLOGY
Mean corpuscular volumes (MCV) statistically significantly lower in main study males at 25 and 150 mg/kg/day than in concurrent controls were without toxicological significance, because there was a lack of dose-relationship in males and females were unaffected at all dose levels.
CLINICAL CHEMISTRY
Serum total cholesterol statistically significantly lower in recovery females at 1000 mg/kg/day than in concurrent controls at the end of the recovery period was considered to be fortitious and of no toxicological importance, because of a lack of confirmatory findings in treated main study animals at the end of the treatment period.
URINALYSIS
Urine volume statistically significantly higher and urine osmotic pressure statistically significantly lower in recovery females at 1000 mg/kg/day than in concurrent controls at the end of the recovery period were considered to be fortitious and of no toxicological importance, because of a lack of confirmatory findings in treated main study animals at the end of the treatment period.
NEUROBEHAVIOUR
In view of a lack of dose relationship, forelimb grip strength statistically significantly lower in males at 150 mg/kg/day than in concurrent controls at the end of the treatment period was not considered to be toxicologically relevant.
ORGAN WEIGHTS
There were no changes in organ weights or organ to terminal bodyweight ratios attributable to treatment with the test material. At the end of the treatment period, epididymis weight to terminal bodyweight ratios were statistically significantly higher at 150 mg/kg/day than in concurrent controls. In view of a lack of dose relationship, this difference was not considered to be toxicologically relevant. At the end of the recovery period, male kidney weights statistically significantly lower than in concurrent controls were also not attributable to treatment.
GROSS PATHOLOGY AND NON-NEOPLASTIC HISTOPATHOLOGY
Macroscopic or microscopic pathology findings, toxicologically, did not distinguish treated animals from concurrent controls and therefore were not attributable to treatment with the test material. In view of the absence of relevant findings in main study animals, recovery animals were not histologically examined. - Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
- Dose descriptor:
- NOEL
- Effect level:
- 25 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: This NOEL was derived from transient salivation seen in male animals at 150 and 1000 mg/kg/day just after administration. This finding was not considered to be an indication of neurotoxicity or to represent an adverse effect.
- Dose descriptor:
- NOEL
- Effect level:
- < 25 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: This NOEL was derived from transient salivation seen in female animals at 25, 150 and 1000 mg/kg/day just after administration. This finding was not considered to be an indication of neurotoxicity or to represent an adverse effect.
- Critical effects observed:
- not specified
- Conclusions:
- There were no adverse effects in the present study. Therefore, the "No Observerd Adverse Effect Level" (NOAEL) was the highest dose level tested, i.e. 1000 mg/kg/day in both sexes.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
The NOAEL for systemic toxicity in adult male and female rats after 4 weeks of oral treatment with ADK STAB FP-800 was the highest tested dose of 1000 mg/kg/day. This does not necessitate any classification regarding repeated exposure according to European classification rules [DIRECTIVE 67/548/EEC and REGULATION (EC) 1272/2008].
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.